Replies to post #714418 on NorthWest Biotherapeutics Inc (NWBO)

[abc1212]

Was good until your maths went a bit wrong.

There are 200,000 GBM patients worldwide each year. After UK approval MD's worldwide will start directing their patients to DCVAXL. With a patient's life depending on it Im sure at least 5% to 10% can afford DCVAXL treatment of let's say $150k. So let's assume 1000 patients of these 200,000 patients worldwide will, after UK approval, get DCVAXL treatment in 2025 x $150k = $150 million revenue x 10 multiplier makes a deserved 1.5 billion market cap for NWBO, which should take us above $1. However, the problem remains OTC.

As you said, 200,000 worldwide and if you took your lowest figure of 5%, that would be 10,000 not 1000

Going by your figures with a 10x multiple, that would give us an SP of over $10

[theorysuit]

The problem is NWBO hasn't even started on pricing model or hiring contractors for the NICE submission. That should tell you they don't have plans to commercialize. The leverage they have in actual buyout depends solely on UK approval. And that is not really much leverage at all. UK is a small market, and that is mostly due to the reimbursement and the size of their market. You want leverage submit to the US or EU.